[HTML][HTML] Gene therapy for skin fragility diseases: the new generation
G Bilousova - Journal of Investigative Dermatology, 2019 - Elsevier
G Bilousova
Journal of Investigative Dermatology, 2019•ElsevierEx vivo gene therapy is a promising approach to treat devastating skin fragility diseases.
March et al. and Takashima et al. report that programmable nucleases—TALENs and
CRISPR/Cas9—can safely and efficiently correct genetic defects in cultured adult skin cells,
paving the way for broader clinical applications of gene therapies in dermatology.
March et al. and Takashima et al. report that programmable nucleases—TALENs and
CRISPR/Cas9—can safely and efficiently correct genetic defects in cultured adult skin cells,
paving the way for broader clinical applications of gene therapies in dermatology.
Ex vivo gene therapy is a promising approach to treat devastating skin fragility diseases. March et al. and Takashima et al. report that programmable nucleases—TALENs and CRISPR/Cas9—can safely and efficiently correct genetic defects in cultured adult skin cells, paving the way for broader clinical applications of gene therapies in dermatology.
Elsevier